{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["nivolumab","vinblastine"],["nivolumab"]],"indication":"elderly Hodgkin lymphoma with coexisting medical conditions","name":"NIVINIHO","nct_id":"NCT03580408","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=niviniho-nct03580408. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)\n\nConsolidation treatment:\n\nIt depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :\n\n* For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.\n* Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)\n* In case of progressive disease , patients will be considered in treatment failure.","label":"Experimental","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-08-12","type":"ACTUAL"},"conditions":["Hodgkin Lymphoma","Coexisting Medical Conditions"],"enrollment":{"count":64,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Vinblastin","otherNames":[],"type":"DRUG"}],"last_update":"2022-08-19","lead_sponsor":"The Lymphoma Academic Research Organisation","official_title":"A Prospective Phase II Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients Aged 61 Years And Older, With Classical Hodgkin Lymphoma And Coexisting Medical Conditions.","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-02-19","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Metabolic Response (CMR) rate (Deauville scale 1-3) at the end of treatment","timeFrame":"12 months"}],"references":[{"citation":"Lazarovici J, Amorim S, Bouabdallah K, Fournier M, Guidez S, Molina L, Morschhauser F, Delapierre B, Gastinne T, Laribi K, Launay V, Slama B, Belmecheri N, Casasnovas RO, Corby A, Durot E, Feugier P, Nicolas-Virelizie E, Sibon D, Berriolo-Riedinger A, Edeline V, Borght TV, Damotte D, Traverse-Glehen A, Ribrag V, Andre M. Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study. Haematologica. 2026 May 28. doi: 10.3324/haematol.2025.300166. Online ahead of print.","pmid":"42206423","type":"DERIVED"}],"start_date":{"date":"2018-08-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT03580408"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/niviniho-nct03580408"}